118 related articles for article (PubMed ID: 9714341)
1. Antitumor activity of a novel orally effective nucleoside, 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine.
Miura S; Yoshimura Y; Endo M; Machida H; Matsuda A; Tanaka M; Sasaki T
Cancer Lett; 1998 Jul; 129(1):103-10. PubMed ID: 9714341
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity.
Miura S; Yoshimura Y; Endo M; Satoh H; Machida H; Sasaki T
Cancer Lett; 1999 Oct; 144(2):177-82. PubMed ID: 10529018
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models.
Zajchowski DA; Biroc SL; Liu HL; Chesney SK; Hoffmann J; Bauman J; Kirkland T; Subramanyam B; Shen J; Ho E; Tseng JL; Dinter H
Int J Cancer; 2005 May; 114(6):1002-9. PubMed ID: 15645422
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor effect of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine on peritoneal dissemination models of gastrointestinal cancers.
Miura S; Endo Y; Yoshimura Y; Endo M; Yonemura Y; Sasaki T
Oncol Rep; 2002; 9(6):1319-22. PubMed ID: 12375041
[TBL] [Abstract][Full Text] [Related]
5. The antitumor mechanism of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)-cytosine: effects of its triphosphate on mammalian DNA polymerases.
Miura S; Yoshimura Y; Satoh H; Izuta S
Jpn J Cancer Res; 2001 May; 92(5):562-7. PubMed ID: 11376566
[TBL] [Abstract][Full Text] [Related]
6. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
Tanaka M; Matsuda A; Terao T; Sasaki T
Cancer Lett; 1992 May; 64(1):67-74. PubMed ID: 1596880
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
9. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor activity of a novel nucleoside, 4'-thio-2'-deoxy-2'-methylidenecytidine.
Miura S; Tanaka M; Yoshimura Y; Satoh H; Sakata S; Machida H; Matsuda A; Sasaki T
Biol Pharm Bull; 1996 Oct; 19(10):1311-5. PubMed ID: 8913503
[TBL] [Abstract][Full Text] [Related]
11. Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
Matsuda A; Nakajima Y; Azuma A; Tanaka M; Sasaki T
J Med Chem; 1991 Sep; 34(9):2917-9. PubMed ID: 1895307
[No Abstract] [Full Text] [Related]
12. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration.
Takahashi T; Kanazawa J; Akinaga S; Tamaoki T; Okabe M
Cancer Chemother Pharmacol; 1999; 43(3):233-40. PubMed ID: 9923554
[TBL] [Abstract][Full Text] [Related]
13. DNA polymerases as targets of anticancer nucleosides.
Miura S; Izuta S
Curr Drug Targets; 2004 Feb; 5(2):191-5. PubMed ID: 15011952
[TBL] [Abstract][Full Text] [Related]
14. Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
Zhang M; Endo Y; Sasaki T
Int J Oncol; 1999 Mar; 14(3):543-9. PubMed ID: 10024689
[TBL] [Abstract][Full Text] [Related]
15. A novel radiochemical approach to 1-(2'-deoxy-2'-[(18) F]fluoro-β-d-arabinofuranosyl)cytosine ((18) F-FAC).
Meyer JP; Probst KC; Trist IM; McGuigan C; Westwell AD
J Labelled Comp Radiopharm; 2014 Sep; 57(11):637-44. PubMed ID: 25257474
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
[TBL] [Abstract][Full Text] [Related]
17. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
Niitsu N; Ishii Y; Matsuda A; Honma Y
Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
[TBL] [Abstract][Full Text] [Related]
18. Novel arabinofuranosyl derivatives of cytosine resistant to enzymatic deamination and possessing potent antitumor activity.
Bobek M; Cheng YC; Bloch A
J Med Chem; 1978 Jul; 21(7):597-8. PubMed ID: 276611
[No Abstract] [Full Text] [Related]
19. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
[TBL] [Abstract][Full Text] [Related]
20. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.
Mima S; Kakinuma C; Higuchi T; Saeki K; Yamada T; Uematsu R; Ishino M; Kito N; Nishikawa H; Kuniyoshi H; Matsumoto T; Fujiwara H; Paradiso LJ; Shimada Y; Iwamura H
J Pharmacol Exp Ther; 2018 Jul; 366(1):125-135. PubMed ID: 29653962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
